Leadership

Scientist and entrepreneur leading WuXi since its founding in 2000. Ph.D. in Organic Chemistry from Columbia University. Awards and honors include "2018 SAPA Distinguished Achievement Award", "2018 The 40 Most Influential People in Pharmaceutical Industry in Commemoration of the 40th Anniversary of Reform and Opening-up", "2016 CBA Brilliant Achievement Award", "2015 SCRIP Executive of the Year Award", "2015 The 25 Most Influential People in Biopharma", "2009 The 60 Most Influential People during 60 Years Pharmaceutical Development in China", "2008 Forbes 25 Notable Chinese-Americans", and "2007 Ernst & Young Entrepreneur of the Year China".

Co-CEO at WuXi AppTec. With experience in operational excellence, financial management and global business expansion, Mr. Hu has demonstrated his extraordinary leadership to help the business expand further. Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox. His earlier career spanned managerial and financial positions at Biogen and Merck respectively. Mr. Hu has an MBA and Master's degree in Chemistry from Carnegie Mellon University.

With more than 20 years of experience in the pharmaceutical industry, Johnathan has over 14 years of clinical trial management experience in the United States, has participated in and led a number of early-phase projects, and managed Phase III studies, including the successful launch of leukemia and oncology indications for Gleevec and Zoledronate during his work at Novartis, USA. After returning to China in 2010, he worked at the Bayer Global R&D Center in clinical project management, and for Roche (China) as head of the region for Roche's global program. In 2014, he served as the Head of Project Management at IQVIA (Greater China), where he was instrumental in leading the departments significant growth in size, expertise, and project success. Johnathan received his MD from Capital Medical University in 1993. In 1997, he obtained his Masters in BMS and Biomolecular Science from NYU.

Rich experience in global preclinical and Phase I-III oncology drug development, translational science and medicine in commercial and academic settings. Formerly CEO and CMO of several Biopharma companies, the Founder and Chairman of BioNumerik Pharmaceuticals, served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. MD from the University of Missouri, School of Medicine, and Medical Oncology fellowship at Johns Hopkins.

With more than 25 years of industry experience, Becky has held executive leadership positions in both large and mid-size CROs for almost 2 decades. Prior to joining WuXi Clinical in 2009, she served as Vice President of Operations at INC Research (now Syneos) where she led both the Internal Medicine and Women's Health divisions. She also coordinated resources for project management and clinical operations and supervising professional services groups, including project initiation, patient recruitment, and contract management. Becky started her career at Pharmaco (now PPD), where she served as the director of several therapeutic areas followed by appointment to the role of Executive Director of Project Management for the entire North American PM team of over 250 professionals. Becky’s degree is in Psychology from the University of Texas at Austin.

Dr. Shen was co-founder, President & CEO of Pharmapace, Inc., a consulting and CRO company to the biopharma industry, which was acquired by WuXi AppTec in 2019. He has a highly accomplished career in leading clinical organizations to support drug development programs. He has directly worked on approximately 30 investigational new drug projects and played leading roles in regulatory submissions that led to 7 drug approvals in both the US and European Union. Dr. Shen has served as senior statistical advisor to numerous biopharma companies as well as member of data/safety monitoring committees. He is a fellow of the American Statistical Association (ASA) and has served as past President of the San Diego Chapter of ASA.   

Alfonso has been in the clinical industry for more than 34 years. Prior to joining WuXi Clinical, he served as CEO and Chairman of the Board of Directors of Anaclim LLC, a CRO company focused on the inclusion of racially balanced people in clinical trials. Prior to this, Alfonso was an executive at Eli Lilly and has accumulated 21 years of experience in various positions, including 7 years of working as CMO and VP of Global Clinical Research. Born in Mexico City, he also received professional training in internal medicine, infectious diseases and clinical microbiology at the Cleveland Clinic in Cleveland, Ohio. Alfonso has not only received different academic and research awards, but also holds many professional-level licenses and certificates. He is a highly authoritative representative member of many associations.

Dr. Wang has worked on designing, implementing, analyzing, and reporting all phases of clinical trials over 20 years across a wide spectrum of biopharmaceuticals and medical devices. He has extensive experience in regulatory submissions, interactions with regulatory authorities, product in-licensing, and commercial development. Dr. Wang’s current research interests include applying innovative statistical methodologies into clinical trial designs. He has been providing extensive consultation to clients on study designs and lectures both internally and externally. Prior to joining WuXi Clinical, he worked for PAREXEL as senior director and head of biostatistics, Asia-Pacific Region. Before that, he had senior roles with global pharmaceutical and medical device companies in the US including St. Jude Medical (now Abbott ) and Allergan. Dr. Wang received his PhD degree in Mathematics and completed his postdoctoral fellowship in Biostatistics and Epidemiology in the US.

David has over 25 years of experience in biostatistics, data management, and strategic management. David's clinical development experience covers drugs, biologics, and devices and has extensive experience in a wide range of therapeutic areas, including oncology, heart disease, central nervous system, immunology, and infectious diseases. David has successfully designed the proof-of-concept endpoints and research, and the project he was in charge of has been approved after it was submitted to the FDA. David is committed to establishing data management services in Asia and has been involved in the development of data management systems and processes for more than 25 years.

With more than 35 years of executive management experience, Natasha worked for PAREXEL contributing to the company's early significant growth. During her 23 year career at PAREXEL, she held various senior management positions and was one of the leading contributors to their rapid growth. Thereafter, Natasha held a variety of senior management positions in several non-profit and for-profit start-ups, providing leadership support in general management, sales and marketing, account management, strategic planning, and organizational development and restructuring. Natasha holds a Bachelor's degree in Mathematics from Boston University and a Master's degree in Biostatistics from Harvard University.